Steward Health Care System

Return to Results

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

new search

Trial Conditions
  • Advanced Prostate Cancer
  • Prostatic Neoplasms
What is the purpose of this trial?

The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.

Date & Status

Recruiting

Who can Participate?

Eligibility

Ages:
18 and older

Gender:
Male

Eligibility

Inclusion Criteria:

- subjects must be at least 18 years of age

- subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent
their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to
enrollment

- subjects must understand and sign an informed consent form

Exclusion Criteria:

- none

Gender: Male
Steward Physician(s)
  • Candice McCoy, MD
Trial Interventions
Biological
  • sipuleucel-T
Physician Researcher

Investigator Name:

  • Candice McCoy, MD

Other Information

Sponsor: Dendreon
Phase: N/A
Trial ID: NCT01306890
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions